Private Trust Co. NA Sells 576 Shares of Gilead Sciences, Inc. $GILD

Private Trust Co. NA reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 14.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,285 shares of the biopharmaceutical company’s stock after selling 576 shares during the quarter. Private Trust Co. NA’s holdings in Gilead Sciences were worth $364,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in GILD. One Wealth Advisors LLC lifted its position in Gilead Sciences by 34.8% in the 2nd quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock valued at $1,016,000 after acquiring an additional 2,364 shares in the last quarter. Ariel Investments LLC lifted its position in Gilead Sciences by 7.7% in the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock valued at $48,229,000 after acquiring an additional 30,630 shares in the last quarter. Golden State Wealth Management LLC lifted its position in Gilead Sciences by 14.5% in the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company’s stock valued at $97,000 after acquiring an additional 109 shares in the last quarter. Covea Finance increased its stake in shares of Gilead Sciences by 69.5% in the 2nd quarter. Covea Finance now owns 51,700 shares of the biopharmaceutical company’s stock worth $5,732,000 after purchasing an additional 21,200 shares in the last quarter. Finally, Swedbank AB increased its stake in shares of Gilead Sciences by 0.8% in the 1st quarter. Swedbank AB now owns 2,118,632 shares of the biopharmaceutical company’s stock worth $237,393,000 after purchasing an additional 16,663 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $123.11 on Tuesday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a 1-year low of $85.60 and a 1-year high of $124.11. The firm has a market capitalization of $152.76 billion, a P/E ratio of 24.52, a price-to-earnings-growth ratio of 0.84 and a beta of 0.34. The company’s 50-day moving average is $115.27 and its 200 day moving average is $110.62.

Gilead Sciences (NASDAQ:GILDGet Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period last year, the company posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were paid a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.6%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is 62.95%.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $354,240.00. Following the completion of the sale, the insider directly owned 110,193 shares in the company, valued at approximately $13,011,589.44. The trade was a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $295,200.00. Following the sale, the chief financial officer owned 157,055 shares of the company’s stock, valued at $18,545,054.40. The trade was a 1.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,500 shares of company stock worth $8,281,540 over the last three months. Corporate insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Royal Bank Of Canada upped their price objective on Gilead Sciences from $98.00 to $100.00 and gave the stock a “sector perform” rating in a research note on Wednesday, October 8th. The Goldman Sachs Group upped their target price on shares of Gilead Sciences from $105.00 to $108.00 and gave the stock a “neutral” rating in a report on Friday. Needham & Company LLC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price for the company in a report on Friday, July 25th. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Finally, UBS Group upped their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $121.14.

Read Our Latest Research Report on Gilead Sciences

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Featured Stories

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.